SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (10056)4/30/2007 11:30:40 AM
From: rkrw  Read Replies (1) | Respond to of 10280
 
Any idea what the $/Rx is for brovana?

Will be interesting to see what the sleep market looks like as ambien generics take hold, how much market demand was on the sidelines etc.



To: Robohogs who wrote (10056)5/8/2007 12:45:47 AM
From: Robohogs  Read Replies (2) | Respond to of 10280
 
April 27 week data:

L 139,007
MDI 55,471

Share was up slightly for Lunesta TRx although Lunesta NRx share was down 30 bps due to generic Ambien launch. Lunesta week over week was up about 1% for NRx and half that for TRx. I have not seen brovana.

Jon


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News